SYNB 1020

Drug Profile

SYNB 1020

Alternative Names: SYNB-1020

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synlogic
  • Class Probiotics
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inborn urea cycle disorders
  • Preclinical Hyperammonaemia

Most Recent Events

  • 09 Nov 2017 Pharmacodynamics and adverse events data from a phase I trial in Healthy volunteers released by Synlogics
  • 08 Nov 2017 Synlogic plans a phase Ib/II study in Urea cycle disorders in 2H 2018
  • 08 Nov 2017 Synlogic plans a phase Ib/II trial for Hyperammonaemia in 1H 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top